Prevalence of Contrast Nephropathy in Type 2 Diabetes Patients With Microalbuminuria

Trial Profile

Prevalence of Contrast Nephropathy in Type 2 Diabetes Patients With Microalbuminuria

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Linagliptin (Primary) ; CD26 antigen inhibitors
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms VCG4
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 30 Aug 2018 to 30 Nov 2018.
    • 31 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Sep 2018.
    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top